Curcumol inhibits the proliferation and metastasis of melanoma via the miR-152-3p/PI3K/AKT and ERK/NF-κB signaling pathways

Ning Ning1#, Sulai Liu1,4,5#, Xiehong Liu1,3, Zeyu Tian1, Yu Jiang1,3, Nanhui Yu1,3, Boyu Tan1, Hao Feng1, Xing Feng2, Lianhong Zou1,3#

1. First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, Hunan, China
2. Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, Hunan, China
3. Hunan Provincial Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Changsha, Hunan, China
4. Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China
5. Hunan Provincial Institute of Emergency Medicine, Hunan Provincial People's Hospital, Changsha, Hunan, China

#These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Abstract

Melanoma is the most aggressive and treatment-resistant form of skin cancer. Curcumol is a Chinese medicinal herb traditionally used as a cancer remedy. However, the molecular mechanisms underlying the anticancer activity of curcumol in melanoma remains largely unknown. In the present study, we observed that Curcumol decreased mouse melanoma B16 cell proliferation and migration. The xenograft tumor assay showed that curcumol reduced melanoma volume and lung metastasis. Curcumol upregulated the expression of E-cadherin and downregulated the expression of N-cadherin, MMP2 and MMP9 in mouse melanoma B16 cell. Western blot analysis revealed that curcumol reduced the translocation of p65 to the nucleus and decreased p-ERK. Furthermore, curcumol attenuated c-MET, P13K and p-AKT protein expression and upregulated miR-152-3p gene expression. The dual-luciferase reporter assay indicated that c-MET was a target gene of miR-152-3p. Reduced expression of miR-152-3p partially attenuated the effect of curcumol on mouse melanoma B16 cell proliferation and migration. The decrease in c-MET, P13K and p-AKT protein expression following curcumol treatment in mouse melanoma B16 cells was notably attenuated by the miR-152-3p inhibitor. Taken together, our findings suggested that curcumol attenuated melanoma progression and concomitantly suppressed ERK/NF-κB signaling and promoted miR-152-3p expression to inactivate the c-MET/PI3K/AKT signaling pathway.

Key words: Curcumol; Melanoma; miR-152-3p; c-MET/PI3K/AKT signaling pathway; ERK/NF-κB signaling pathway

Introduction

Melanoma is the most prevalent, as well as the most aggressive and treatment-resistant malignant skin cancer. Melanoma causes ~80% of skin cancer-associated mortalities worldwide, and its incidence has increased by 45% since the 20th century, with an annual percentage change being estimated at 3.1% 3,4. The rising incidence and mortality of melanoma worldwide, as well as its high propensity for metastasis, highlights the urgency of exploring the molecular mechanism governing the progression of melanoma and developing effective strategies for melanoma.

Curcuma is traditionally used to treat various ailments, including cacochylia, traumatic hematoma,
parasitic infection and tumorous diseases. \( \text{C}_{15}\text{H}_{24}\text{O}_{2}-(3s-(3a,3aa,5a,6a,8ab))-\text{octahydro-3-methyl-8-methylene-5-(1-methylethyl)-6h-3a,6-epoxyazulen-6-ol} \) (curcumol) (Figure 1A) is a polyphenol compound isolated from the ethanol extracts of Curcuma wenyujin. Curcumol contains the structure of guaiane-type sesquiterpenoid hemiketal, and it is related to the potential anticancer effects of curcumol. Curcumol has been established as an antitumor compound against multiple types of cancer, including liver, gastric, and lung cancer. Curcumol exhibits anti-hepatic fibrosis activity via the downregulation of transforming growth factor-\( \beta \)1 and cytochrome P450 9 and the inhibition of the phosphatidylinositol 3'-kinase (PI3K) and nuclear factor kappa-B (NF-\( \kappa \)B) pathways. Curcumol inhibits hepatocarcinoma cell proliferation through activating the p53 and pRB pathways. Curcumol decreases MMP and IDH1 to induce gastric adenocarcinoma cell apoptosis. Curcumol inhibits non-small-cell lung cancer cell migration and invasion by suppressing focal adhesion kinase (FAK) and MMP and induces apoptosis via a caspase-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells. However, the molecular mechanisms underlying the anticancer activity of curcumol in melanoma have not been elucidated.

MicroRNAs (miRNAs) are a class of small, noncoding RNA molecules containing approximately 19~22 nucleotides. miRNAs mostly bind to the 3'-untranslated region (3'-UTR) of the target mRNAs, regulating gene expression at the posttranscriptional level. miR-152 is a member of the miR-148/152 family, which is expressed not only in normal tissues but also in numerous tumors, such as colorectal tumors and breast and human gastric tumors. miR-152 inhibits cancer stemness, cell proliferation, and tumor angiogenesis. Luan et al. found that miR-152-3p was a target that decreased the expression of Cellular mesenchymal-epithelial transition factor (c-MET) and then suppressed melanoma progression and invasion via the PI3K/Akt/mTOR signaling pathway. Therefore, these studies showed that miR-152-3p could be a novel therapeutic small molecule to suppress cancer.

In this study, we assessed the effect of curcumol on mouse melanoma B16 cells. We hypothesized that curcumol suppresses the ERK/NF-\( \kappa \)B signaling pathway and upregulates miR-152-p to suppress the c-MET/PI3K/AKT pathway and inhibit melanoma cell growth and invasion. The study elucidated the possible molecular mechanisms responsible for curcumol anticancer activity.

Materials and Methods

Cell culture

Mouse B16 melanoma cells were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured according to the manufacturer's instructions. Briefly, we cultured these cells with Dulbecco's modified Eagle's medium (DMEM). Additionally, 10% FBS and 1% penicillin/streptomycin were added (Gibco, Rockville, MD, USA) to culture melanoma cell lines. Cell incubators in a humidified atmosphere containing 5% CO\(_2\) were employed for all cell cultures.

Cell viability assay

We assessed cell viability using a Cell Counting Kit-8 assay (CCK-8) following the protocol from the manufacturer (Dojindo, Tokyo, Japan). We seeded \( 2 \times 10^3 \) cells in 96-well plates and incubated at 37 \(^\circ\)C for 24 h. The cells were treated with the indicated concentrations (0, 25, 50, 100, and 200 µM) of curcumol for 24 h, 48 h, or 72 h in a humidified chamber containing 5% CO\(_2\). Then, we added 10 \( \mu \)l CCK-8 reagent into each well and incubated for 1 h at 37 \(^\circ\)C. A microplate reader (Bio-Tech, USA) was used to determine the absorbance of cells at 450 nm (OD450).

Colony formation assay

Mouse B16 melanoma cells were seeded into 60-mm dishes (200 cells/dish) for 24 h and then incubated with 0, 25, 50, 100, and 200 µM curcumol for 2 weeks to form colonies. Then, the colonies were washed with PBS three times. Next, the cells were fixed with methanol for 15 min, and they were stained with 0.1% crystal violet for 30 min at room temperature. Finally, we counted the number of colonies containing \( \geq 50 \) cells under a microscope. Each assay was performed in triplicate.

Xenograft tumor assay

The xenograft tumor growth assay was performed in four-week-old male C57 mice (purchased from Shanghai SLAC Laboratory Animal Co., Ltd, China), and the animal experiments were approved by the Hunan Provincial People's Hospital. First, \( 2 \times 10^6 \) mouse melanoma B16 cells were suspended in sterile saline (200 µl) or injected subcutaneously into the right lower paw and intravenously into the tail vein of mice. Curcumol (20 mg/kg) was injected intraperitoneally into mice 3 times per week. Tumor volumes were calculated according to the formula \((0.5 \times \text{length} \times \text{width})\) every 5 days. After 30 days, the mice were sacrificed, we
tested the tumor volume in the right lower paw and harvested xenograft pulmonary tumors immediately.

**Wound healing assay**

We used a wound healing assay to evaluate the migration ability of mouse B16 melanoma cells. Mouse B16 melanoma cells were plated at a concentration of 1×10⁵ cells/ml and incubated for 24 h, and a 200-μl pipette tip was used to scratch the cell layers to form wound gaps. The cells were incubated with 0, 50 and 100 μM curcumol for the indicated times (0, 24 and 48 h). The cells were photographed under a microscope to record the wound width. Wound healing was analyzed using ImageJ software.

**Western blot assays**

Cells were washed with ice-cold PBS and RIPA buffer with protease inhibitor was used to extract the total protein from tissues and cells, and protein concentrations were quantified with a BCA Protein Assay Kit (Beyotime, China). Briefly, equal amounts of protein (20 μg) were separated by 10% or 12% SDS-PAGE and transferred to PVDF membranes (Millipore, USA). Subsequently, the membranes were blocked in 5% nonfat milk in TBST for 1 h at room temperature and then incubated overnight with diluted primary antibodies at 4 °C followed by incubation with HRP-conjugated secondary antibody. GAPDH was used as a control. Proteins were visualized using the Luminescent Image Analyzer (ImageQuant LAS500, GE, USA), and densitometric analysis was performed using ImageJ software.

**Transwell Migration and Invasion Assay**

Cell migration was measured using a Transwell migration assay according to the manufacturer’s instructions. The mouse B16 melanoma cells were mixed by the blowing method and added to the serum-free DMEM for incubator. After the cell concentration was adjusted to 5×10⁵ cells/ml, 800 μl of DMEM containing 5% FBS was added to the lower chamber of the Transwell permeable support, and 200 μl of cell suspension was added to the upper chamber. Before the experiment, 10 μg/ml collagen was added into the Transwell at 50 μl/well. The cells were then cultured with the indicated concentrations (0, 50 and 100 μM) of curcumol in an incubator for 24 h followed by fixation with 4% paraformaldehyde and staining with crystal violet for 20 min. Microscopic images were used to observe the migration and invasion of cells, and visual fields were randomly selected and photographed. ImageJ (1.48 v) software (National Institutes of Health, Bethesda, MD, USA) was used to obtain an average cell count of the four stained membrane images.

**Luciferase reporter assay**

The wild-type and mutant 3’-untranslated region (3’-UTR) fragment of c-MET containing the putative binding sequences of miR-152-3p were cloned into the pGLO2-basic vector (NEB) as wild-type (WT) or mutant (Mut). Mouse B16 melanoma cells were cotransfected with hsa-miR-152-3p mimic or NC and related reporter constructs. Luciferase activity was detected using the Dual Luciferase Reporter Assay System (Promega, USA) after transfection for 48 h according to the manufacturer’s protocol.

**Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)**

We used TRIzol (Invitrogen, Carlsbad, CA, USA) to extract total RNA from mouse B16 melanoma cells according to the manufacturer’s protocol. The 1 μg sample of RNA was reverse transcribed into complementary deoxyribonucleic acid (cDNA) using a PrimeScript RT Reagent Kit (RR047A; TaKaRa, Shiga, Japan). The relative miRNA-152-3P levels were determined by RT-qPCR using the StepOnePlus™ Real-Time PCR System (Applied Biosystems, USA). U6 was used as the internal control. The primers were used as follows: miR-152-3p forward 5′-ACACTCC AGCTGGTCAGTGCATGACAG-3′, and reverse, 5′-CTCAACTGTTGTCGAGTCCGCGAATTCACTG TTGAGCCAAGTT-3′; U6 forward, 5′-CAAATTCGTGGTCCATA-3′, and reverse, 5′-AGTTGCAGG GTCCGAAGTTATC-3′. Relative quantities were determined using the comparative 2-ΔΔCt method.

**Data analysis**

The results of at least three independent datasets are presented as the mean ± standard deviation (S.D.). For statistical analysis, statistical significance was analyzed using Tukey’s multiple comparison tests and one-way analysis of variance. Data analysis was performed with SPSS 16.0. Statistical significance was determined at p< 0.05.

**Results**

**Effect of curcumol on the proliferation of mouse melanoma B16 cells in vitro and in vivo**

To determine whether curcumol influences the proliferation of mouse melanoma B16 cells, we first examined the effect of curcumol on the proliferation of the cells with the CCK-8 assay. Mouse melanoma B16 cells were treated with different concentrations of curcumol (0, 25, 50, 100 and 200 μM) for 0, 24, 48 and 72 h, respectively. As shown in Figure 1B, curcumol decreased cell viability in a dose-dependent and time-dependent manner, and compared to the control, 50- and 100-μM curcumol treatment for 48 h reduced
the cell viability by 55%. Second, mouse melanoma B16 cells were incubated with 0, 50 and 100 μM for 2 weeks, and colony formation assays were performed. The results confirmed that curcumol decreased colony formation (Figure 1C and 1D) in a dose-dependent manner, and when curcumol concentration reached 100 μM, the number of colonies decreased by 60% compared to the control.

To further test the function of curcumol in vivo, we established a melanoma xenograft model by subcutaneously injecting mouse melanoma B16 cells. As shown in Figure 1E and 1F, the average tumor volume in the DMSO group was significantly greater than that in the curcumol group after 30 days. These findings suggest that curcumol suppresses the proliferation of mouse melanoma B16 cells and melanoma growth in vivo.

Effect of curcumol on the migration and invasion of mouse melanoma B16 cells and mouse pulmonary metastasis model

Subsequently, we defined the role of curcumol in melanoma metastasis, and we examined the metastatic properties of the cells treated with 50 and 100 μM curcumol for 24 and 48 h in serum-free medium and examined the cells by wound-healing assay. Our data (Figure 2A and 2B) showed that there was a significantly lower migration rate for the cells in the curcumol group compared with the DMSO group. Then, we performed a migration assay to further detect the effect of curcumol on cell migration. As shown in Figure 2C and 2D, curcumol significantly inhibited cell migration in a dose-dependent manner, and 54% inhibition was observed at a concentration of 100 μM Tangeretin.

We observed that curcumol markedly suppressed cell migration in vitro and then examined the effect of curcumol on tumorigenicity and metastasis in vivo. To this end, mouse melanoma B16 cells were injected intravenously into C57 mice. As shown in Figure 2E and 2F, the intrapulmonary metastasis rate of mouse melanoma B16 cells was 80% in the DMSO group, and there was a lower 20% metastasis rate in the curcumol group. Taken together, these data support an important role for curcumol in the suppression of invasion and metastasis in vivo and in vitro.

![Figure 1](http://www.jcancer.org)

Figure 1. Curcumol inhibits the proliferation of mouse melanoma B16 cells in vitro and in vivo. (a) Molecular structure of curcumol. (b) Mouse melanoma B16 cells were treated with the indicated concentrations of curcumol (0, 25, 50, 100 and 200 μM) for 24, 48 and 72 h, respectively. CCK-8 assays were used to measure cell viability. (c) Mouse melanoma B16 cells were incubated with 0, 25, 50, 100 and 200 μM curcumol for 2 weeks from colonies. Then, the cells were subjected to a colony formation assay. (d) The graph summarizes the colony formation assay data. (e) The xenograft tumor of mouse melanoma B16 cells formed in C57 mice. (f) Difference in tumor volume between the DMSO group and the curcumol group. Error bars represent the s.d. of the mean. n≥6; *P<0.05; **P<0.01; ***P<0.001.
Figure 2. Curcumol reduces the migration and invasion in mouse melanoma B16 cells and mouse pulmonary metastasis model. Mouse melanoma B16 cells were treated with 50 or 100 μM curcumol or DMSO for 24 and 48 h in serum-free medium, respectively. (a) Wound healing assays were used to measure cell migration. (b) Graph of cell migration rate. (c) Mouse melanoma B16 cells were treated with 50 and 100 μM curcumol or DMSO for 48 h. Representative images of Transwell membranes stained with crystal violet (×10). Scale bar=25 μm. (d) Graph of the number of invasion cells. (e) Mouse pulmonary metastasis model. (f) Difference in the number of lung nodules between the DMSO group and the curcumol group. The results represent the average of three experiments. Error bars represent the s.d. of the mean; *P<0.05; **P<0.01; ***P<0.001.

Curcumol modulates the expression of MMP2/9 and E/N-cadherin in mouse melanoma B16 cells

Matrix metalloproteinase (MMPs) are the principal enzymes in extracellular matrix (ECM) degradation 25. It has been shown that elevated expression of MMP2 and MMP9 is positively correlated with tumor progression, metastasis, and poor prognosis 26. Curcumol has been shown to decrease the MMP to inhibit lung adenocarcinoma cancer cell migration and invasion 12,13. Furthermore, our results indicated that curcumol decreased the expression of MMP2 and MMP9 in mouse melanoma B16 cells (Figure 3A and 3B).

Epithelial to mesenchymal transition (EMT) refers to the loss of cell adhesion, repression of E-cadherin expression and increasing cell mobility 27. The aberrant activation of EMT promotes tumor cell invasion and dissemination 28. Yan et al found that curcumol altered the levels of E-cadherin and N-cadherin in a dose-dependent manner in a nasopharyngeal carcinoma cell xenograft model 29. Our results indicated that curcumol attenuated the expression of MMP2 and MMP9; therefore, we sought to determine whether curcumol was responsible for regulating epithelial-mesenchymal transition(EMT) in mouse melanoma B16 cells. Our data showed that curcumol increased the expression of E-cadherin and prominently decreased the expression of N-cadherin (Figure 3C and 3D). Taken together, these data clearly demonstrate that curcumol limited the metastatic process of mouse melanoma B16 cells by regulating the ECM and EMT.

Effect of curcumol on the PI3K/Akt and ERK/NF-κB pathways in mouse melanoma B16 cells

Cellular c-MET acts as an oncogene in malignant melanoma, and c-MET expression is markedly increased in melanoma cells 24. It has been demonstrated that c-MET enhanced melanoma cell proliferation and invasive capacity and protected cells from apoptosis via the PI3K/AKT signaling pathway 24,30. Thus, based on our results showing that curcumol affected mouse melanoma B16 cell proliferation and invasion, we next investigated the effect of curcumol on c-MET, PI3K and Akt protein expression. Western blot analysis revealed that the c-MET and PI3K protein levels in the curcumol group were significantly lower than those in the control group. Additionally, curcumol attenuated Akt phosphorylation in mouse melanoma B16 cells (Figure 4A and 4B).
Figure 3. Curcumol suppresses the expression of MMP2/9 and E/N-cadherin in mouse melanoma B16 cells. Mouse melanoma B16 cells were treated with the indicated concentrations of curcumol (50 and 100 μM) or DMSO for 48 h. Then, (a) the levels of MMP2, MMP9 and actin were examined by Western blot analysis. (b) Relative levels of MMP2 and MMP9 compared with actin. (c) The levels of E-cadherin, N-cadherin and actin were examined by Western blot analysis. (d) Relative levels of E-cadherin and N-cadherin compared with actin. The results represent the average of three experiments. Error bars represent the s.d. of the mean; *P<0.05; **P<0.01; ***P<0.001.

Figure 4. PI3K/Akt and ERK/NF-κB pathways are related to the inhibition of melanoma induced by curcumol. (a) Mouse melanoma B16 cells were treated with 100 μM curcumol or DMSO for 48 h. Then, the levels of c-MET, PI3K, p-AKT, T-AKT and actin were examined by Western blot analysis. (b) Densitometry revealed the fold expression of c-MET and PI3K compared with that of actin, respectively; and densitometry revealed the fold expression of p-AKT compared with that of T-AKT. (c) Mouse melanoma B16 cells were treated with 100 μM curcumol for 48 h or 10 ng/ml TNF-α for 1 h. After this step, cytoplasmic (Cyto) or nuclear (Nuc) extracts were analyzed using antibodies against the indicated proteins. (d) Graph represents the ratio of p-ERK/ERK. (e) Graph represents the levels of p65 Cyto and p65 Nuc relative to the control. The results represent the average of three experiments. Error bars represent the s.d. of the mean; *P<0.05; **P<0.01; ***P<0.001.
Numerous studies have shown that MMP2/9 expression is regulated by NF-κB signaling pathways in melanoma, and curcumin induced HSC-T6 cell death via this pathway. Therefore, we further observed the effects of curcumin on the NF-κB pathway in mouse melanoma B16 cells. We applied tumor necrosis factor alpha (TNF-α) as a positive control in experiments. Our results demonstrate that curcumin significantly increased the phosphorylation of ERK and activation of p65 compared with the control group (Figure 4C-E). Overall, these data indicate that curcumin mediates the inhibition of the PI3K/Akt and NF-κB signaling pathways to modulate migration and invasion in mouse melanoma B16 cells.

Curcumol inhibited mouse melanoma B16 cell growth and metastasis by upregulating miR-152-3p

miR-152-3p is a tumor suppressor gene that is expressed at low levels in melanoma. Therefore, we performed miRNA microarray analysis to determine whether curcumin affects miRNA expression in mouse melanoma B16 cells. The heat map data revealed 69 differentially expressed miRNAs in the 100 μM curcumin group compared with the DMSO group (Figure 5A). Treatment with 100 μM curcumin upregulated 38 miRNAs and downregulated 31 miRNAs. Notably, 100 μM curcumin significantly upregulated miR-152-3p expression, which was greater than a seven-fold change compared with the DMSO group (Table 1 and Figure 5B). To further confirm the data obtained from the miRNA microarray, we used qRT-PCR to examine miR-152-3p expression in mouse melanoma B16 cells. Our results showed that curcumin upregulated the level of miR-152-3p in a dose-dependent and time-dependent manner (Figure 5C and 5D).

The results above clearly indicate that curcumin increases the level of miR-152-3p in mouse melanoma B16 cells. Subsequently, we used siRNA technology to inhibit miR-152-3p expression and investigated

Figure 5. Effect of curcumin on miR-152-3p expression in mouse melanoma B16 cells. (a) Mouse melanoma B16 cells were treated with 50 and 100 μM curcumin or DMSO for 48 h. Heat map of miR related gene expression of curcumin or DMSO treated cells. The blank in the right is the related gene symbol of the heat map. (b) Volcano plot analysis of miR gene in 100 μM curcumin group compare with the DMSO group. The dots represent genes which passed our filtering criteria (P < 0.05 and fold change > 1.2). X axis and Y axis represent log2(fold change) and −log10(P value), respectively. (c) Mouse melanoma B16 cells were treated with 50 and 100 μM curcumin or DMSO for 48 h. (d) Mouse melanoma B16 cells were treated with 100 μM curcumin or DMSO for 0, 24 and 48 h, respectively. miR-152-3p was measured by real-time quantitative PCR. Error bars represent the s.d. of the mean; **P<0.01; ***P<0.001.
whether curcumol prevented mouse melanoma B16 cell proliferation and migration via miR-152-3p. Treatment with siRNA for miR-152-3p downregulated miR-152-3p expression by 85% (Figure 6A), and curcumol led to a reduction in mouse melanoma B16 cell viability, which was significantly reversed by the addition of miR-152-3p inhibitor (Figure 6B). As shown (Figure 6C-F), 100 μM curcumol reduced the migration rate of the mouse melanoma B16 cells and was markedly attenuated by the miR-152-3p inhibitor. Taken together, our data suggest that curcumol prevents mouse melanoma B16 cell proliferation and migration by upregulating the level of miR-152-3p.

Curcumol-mediated suppression of the PI3K/AKT signaling pathway partially depends on miR-152-3p

miR-152-3p, through direct targeting of c-MET, suppresses oral squamous cell carcinoma 34, and our results also demonstrated that miR-152-3p inhibitor reduced the c-MET gene transcription and protein expression (Figure 7A and 7B). We predicted the potential miR-152-3p binding sites in c-MET using Starbase 2.0 (http://www.targetscan.org/vert_71/). Dual luciferase reporter assays showed that a miR-152-3p mimic reduced the luciferase activity of pMIR-c-MET-WT but not that of pMIR-c-MET-MUT in mouse melanoma B16 cells (Figure 7C and 7D).

Table 1. miR gene change in the 100 μM curcumol group compared with the DMSO group.

| miRs   | Fold Change | P-value   | miRs   | Fold Change | P-value   |
|--------|-------------|-----------|--------|-------------|-----------|
| miR-201b | 0.174       | 1.259E-03 | miR-639 | 2.114       | 1.820E-02 |
| miR-183 | 0.240       | 2.455E-04 | miR-95  | 2.144       | 3.548E-04 |
| miR-200b| 0.243       | 6.918E-03 | miR-576-3p | 2.173    | 2.188E-02 |
| miR-145 | 0.266       | 8.913E-05 | miR-1274a| 2.250       | 3.981E-03 |
| miR-876-3p| 0.268       | 2.692E-03 | miR-1228| 2.266       | 2.848E-02 |
| miR-125b| 0.270       | 5.012E-03 | miR-1300| 2.313       | 6.607E-03 |
| miR-888 | 0.275       | 3.981E-04 | miR-565  | 2.514       | 1.862E-02 |
| miR-1290| 0.283       | 8.710E-03 | miR-205  | 2.532       | 2.512E-04 |
| miR-195 | 0.287       | 9.333E-04 | miR-455-5p| 2.732     | 8.318E-04 |
| miR-139-5p | 0.289       | 3.890E-03 | miR-30c-1| 2.751       | 2.570E-03 |
| miR-497 | 0.291       | 4.677E-03 | miR-25   | 2.828       | 3.311E-02 |
| miR-429 | 0.297       | 3.981E-03 | miR-1308 | 2.848       | 1.698E-03 |
| miR-154 | 0.323       | 1.995E-03 | miR-591  | 2.848       | 3.890E-02 |
| miR-1249| 0.332       | 8.318E-03 | miR-224  | 2.908       | 9.772E-03 |
| miR-140-5p| 0.346      | 3.162E-02 | miR-9    | 2.969       | 3.631E-02 |
| miR-204 | 0.349       | 5.623E-03 | miR-923  | 2.990       | 9.772E-04 |
| miR-567 | 0.349       | 1.148E-02 | miR-519  | 2.990       | 6.761E-04 |
| miR-218 | 0.356       | 3.631E-02 | miR-203  | 3.074       | 2.884E-02 |
| miR-149 | 0.376       | 5.129E-03 | miR-1285 | 3.138       | 1.318E-03 |
| miR-200c| 0.376       | 2.138E-03 | miR-200a | 3.458       | 1.549E-04 |
| miR-431 | 0.392       | 8.511E-03 | miR-182  | 3.531       | 1.778E-03 |
| miR-891b| 0.395       | 4.677E-04 | miR-1273 | 3.706       | 1.413E-03 |
| miR-29b-2| 0.415       | 5.012E-03 | miR-494  | 3.758       | 5.012E-05 |
| miR-125b-2| 0.420      | 2.399E-02 | miR-1826| 3.811       | 8.710E-04 |
| miR-342-5p| 0.420      | 3.631E-02 | miR-1248| 4.170       | 3.981E-03 |
| miR-140-3p| 0.438      | 6.607E-03 | miR-675  | 4.170       | 4.898E-04 |
| miR-27b | 0.441       | 5.495E-03 | miR-20b  | 4.377       | 2.570E-04 |
| miR-665-5p| 0.444       | 5.370E-03 | miR-198  | 4.438       | 7.943E-04 |
| miR-141 | 0.448       | 5.129E-04 | miR-19   | 5.134       | 9.772E-04 |
| miR-365 | 0.451       | 8.913E-03 | miR-663b | 5.399       | 7.079E-04 |
| miR-159-9.1| 0.454      | 8.710E-03 | miR-152-3p| 7.362     | 1.445E-05 |
| miR-455-3p| 0.457       | 1.950E-04 | miR-186  | 3.236E-02 |
| miR-186 | 0.460       | 3.236E-02 | miR-199a | 2.455E-02 |
| miR-199a| 0.464       | 2.455E-02 | miR-27a  | 7.413E-03 |
| miR-127-3p| 0.480       | 1.820E-02 | miR-99a  | 6.918E-04 |
| miR-378 | 0.493       | 1.023E-03 |
Based on our results, we used a miR-152-3p inhibitor to further examine the effects of curcumol on MMP2/9 and E/N-cadherin in mouse melanoma B16 cells. As demonstrated in Figure 8A and 8B, the decrease in MMP2 and MMP9 following curcumol-treated mouse melanoma B16 cells was markedly attenuated by the miR-152-3p inhibitor. Additionally, the miR-152-3p inhibitor reversed the curcumol effect by decreasing N-cadherin and increasing E-cadherin (Figure 8C and 8D). These results indicated that curcumol regulated ECM and EMT by miR-152-3p. In addition, the expression of c-MET and PI3K and the phosphorylated form of AKT were considerably upregulated in the curcumol treatment group. In contrast, the miR-152-3p inhibitor led to a marked decrease in c-MET, PI3K and p-AKT levels, and the miR-152-3p inhibitor attenuated the effect of curcumol (Figure 8E-H). In summary, curcumol inhibited mouse melanoma proliferation and migration, largely by enhancing miR-152-3p and downregulating the c-MET/PI3K/AKT pathway.
Figure 7. miR-152-3p represses the expression of c-MET. Mouse melanoma B16 cells were transfected with miR-152-3p NC or miR-152-3p inhibitor for 48 h, and then treated with 100 μM curcumol or DMSO for 48 h. (a) c-MET was measured by real-time quantitative PCR. (b) c-MET protein expression was measured by Western blot. (c) Predicted miRNA binding sites within the 3`-UTR of c-MET mRNA by Starbase 2.0. The pairing between miR-152-3p and the putative binding sites in the 3 `-UTR of c-MET mRNA are shown. (d) Luciferase activity was measured in mouse melanoma B16 cells transfected with the wild-type 3`-UTR and mutant 3 `-UTR c-MET luciferase constructs and a miR-152-3p mimic or a scrambled miRNA control. The results represent the average of three experiments. Error bars represent the s.d. of the mean;*P<0.05; **P<0.01; ***P<0.001.

Discussion

Melanoma is considered to be one of the most malignant cancers, and approximately 200,000 new cases are diagnosed worldwide each year 35. Currently, the major challenges to conventional antitumor drugs include chemotherapy resistance and severe systemic adverse effects 36,37. Therefore, interest has increasingly focused on finding novel and alternative medicines that are safe and effective against melanoma. Curcumin has been reported to possess antitumor and antiviral activities with low cytotoxicity 38. In the present study, we demonstrated that curcumol decreased the expression of c-MET, PI3K and p-AKT by increasing the level of miR-152-3p. Simultaneously, curcumol decreased ERK phosphorylation and prevented the activity of NF-κB, thereby driving the c-MET/PI3K/AKT-dependent and ERK/NF-κB-dependent pathways associated with mouse melanoma B16 cell death (Figure 9).

Curcumol is one of the major monomeric components of Rhizoma Curcumae and is widely used in the treatment of cancer in China 39. Curcumol has a wide range of biological activities, including proliferation inhibition and apoptosis induction of a variety of cancer cells 9-16. Consistent with the aforementioned reports, we found that curcumol decreased mouse melanoma B16 cell proliferation and migration. Curcumol is a multitarget natural anticancer substance, and the main targets involved in different cancers are also different, but the PTEN/PI3K/AKT pathway and the ERK/NF-κB pathway are the main regulatory points for curcumol to inhibit cancer cell growth. Liu et al found that curcumol inhibited colorectal cancer proliferation via modulating PTEN/PI3K/AKT pathways 40. Li et al indicated that curcumol induces cell cycle arrest and apoptosis by inhibiting the IGF-1R/PI3K/Akt signaling pathway in human nasopharyngeal carcinoma CNE-2 cells 41. Our current findings also revealed that the inhibitory effect of curcumol on the proliferation and migration of mouse melanoma B16 cells is related to the inhibition of the PI3K/AKT pathway. Consistent with previous reports 9,31-33,42, our results also showed that curcumol exerted an inhibitory effect on mouse melanoma B16 cells by inhibiting the ERK/NF-κB signaling pathway.
Inhibition of the c-MET pathway is a potential therapeutic strategy against melanoma. Overexpression of c-MET in melanoma cells enhances cell protection from cell death and correlates with a poor clinical outcome, which was shown to be mediated by the activation of the PI3K/AKT pathways. Furthermore, some synthetic cyclic compounds were designed and used to suppress MET kinase activity, such as cabozantinib, foretinib, BMS777607, MGCD-265 and pyrrolo[2,3-b]pyridine.
derivatives. Our data also showed that curcumol decreased the expression of c-MET, which inhibited downstream PI3K/AKT pathways.

A number of studies have revealed that miRNA plays a critical role in health and diseases, including cell growth, migration, apoptosis and cancer cell resistance. A decrease in miR-152 has been proved to be associated with the processes of cell proliferation, invasion and angiogenesis in different neoplasms. In melanoma, miR-152-3p levels are relatively decreased compared to normal mammary tissues. Then, we used miRNA microarrays to test the potential miRNAs that could be regulated by curcumol. miR-152-3p expression was significantly higher in the curcumol treatment group in mouse melanoma B16 cells, which was consistent with the qRT-PCR results. In addition, c-MET plays an essential role in miR-152-regulated PI3K/AKT signaling in osteosarcoma cells. Based on these findings, we hypothesized that curcumol exerts anti-tumor activity, which may be associated with an increase in the level of miR-152-3p to decrease the c-MET in mouse melanoma B16 cells. To test this hypothesis, miR-152-3p that could interact with c-MET was predicted using Starbase 2.0. Western blotting and qRT-PCR results indicated that miR-152-3p reduced the level of c-MET. Moreover, dual luciferase reporter assays confirmed that miR-152-3p directly binds to c-MET. Finally, we found that curcumol inhibits c-MET expression and the downstream signaling pathway PI3k/Akt, and this inhibition effect of curcumol on mouse melanoma B16 cells can be reversed by miR-152-3p inhibitor. These results reveal that curcumol suppressed melanoma cell growth and metastasis by, at least in part, upregulating the level of miR-152-3p and promoting miR-152-3p to bind c-MET.

**Figure 9.** Schematic illustrating the working principle of curcumol related signaling in mouse melanoma B16 cells. We propose that curcumol maintained the level of miR-152-p in mouse melanoma B16 cells, thereby inactivating c-MET/PI3K/AKT-dependent signaling pathway associated with mouse melanoma B16 cell death. In addition, our results also imply that ERK/NF-κB signaling pathway contributes partially in curcumol-mediated effects.
To summarize, this study is the first to demonstrate that curcumol, via the c-MET/PI3K/AKT and ERK/NF-κB signaling pathways, deceases melanoma cell proliferation and migration. Moreover, our research has demonstrated a potential role for curcumol in the treatment of melanoma, and miR-152-3p was targeted by curcumol to treat melanoma. However, due to the unique five-membered and seven-membered ring chemical structure of curcumol, the drug solubility is poor, and the bioavailability is not high. Therefore, further studies are warranted to improve the physical properties and modify the structure of curcumol in a clinical context.

Acknowledgments

This work was financially supported by following funds: China Postdoctoral Science Foundation (Grant No. 2017M620347) / Natural Science Foundation of Hunan Province (Grant No. 2017JJ3171; 2019JJ50327) / Changsha science and technology project (Grant No. Kq1701053) / Key Research and Development Project of Science and Technology Department of Hunan Province (Grant No. 82016SK2044) / Scientific Research Projects of Hunan Health and Family Planning Commission (Grant No. 1320180802) / Project of Hunan Traditional Chinese Medicine Research Program (Grant No. 201977).

Ethics Committee Approval and Patient Consent

Investigations involving humans will have been performed in accordance with the principles of Declaration of Helsinki. And the use of animals in experiments will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education by the New York Academy of Sciences, Ad Hoc Animal Research Committee.

Abbreviations

Curcumol: C15H24O2-(3α-(3α,3aa,5a,6a,8ab))-octahydro-3-methyl-8-methylene-5-(1-methyleryl)-6-h-3,6-epoxyazulen-6-ol
MMP9: matrix metalloprotein-9
MMP2: matrix metalloprotein-2
ECM: extracellular matrix
EMT: epithelial-mesenchymal transition
c-MET: Cellular mesenchymal - epithelial transition factor
PI3K: phosphatidylinositol 3’-kinase
AKT: protein kinase B
ERK: extracellular regulated protein kinases
NF-κB: nuclear factor kappa-B

FAK: focal adhesion kinase
MiRNAs: MicroRNAs
TNF-α: tumor necrosis factor alpha
SPINT2: serine peptidase inhibitor kunitz type 2

Competing Interests

The authors have declared that no competing interest exists.

References

1. Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K. et al. Loss of Phd2 cooperates with BRAF(V600E) to drive melanomagenesis. Nat Commun. 2018; 9: 426.
2. Navarrete-Dechent C, Cordova M, Postow MA, Pulitzer M, Lezzano C, Halpern AC.et al. Evaluation of the Response of Unsectectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases. JAMA Dermatol. 2019. [Epub ahead of print]
3. Trotter SC, Seo N, Winkelmann RR, Olencki T, Bechtle M. A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol. 2013; 6: 18-26.
4. Lines E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009; 129: 1666-1674.
5. Membership of the 5th Pharmacopoeia Commission, Pharmacopoeia Commission of PRC,Pharmacopoeia of the People’s Republic of China (English edition). Chemical Industry Press: Beijing. 2000.
6. Huang LZ, Wang J, Lu FT, Yang FC, Chen X, Hong B. et al. Anti-cancer properties of terpenoids isolated from Rhizoma Curcumae--a revi ew. J Ethnopharmacol. 2012; 43: 406-411.
7. Hikino H, Sakurai Y, Numabe S, Takeomo T. Structure of curcumol. Chem Pharm Bull. 1968; 16: 39-42.
8. Gao P, Wang YW, Weng BX, Li XK, Yang SL, Ye FQ. Synthesis, anti-tumor activity, and structure-activity relationships of curcumol derivatives. J Asian Nat Prod Res. 2014;16: 53-58.
9. Jiang Y, Li ZS, Jiang FS, Deng X, Yao CS, Nie G. Effects of different ingredients of zedoary on gene expression of HSC-T6 cells. World Journal of Gastroenterology. 2005; 11: 6789-6796.
10. Chen G, Wang Y, Li M, Xu T, Wang X, Hong B. et al. Curcumol induces HSC-T6 cell death through suppression of Bcl-2 involvement of PI3K and NF-κB pathways. Eur J Pharm Sci. 2014; 65: 21-28.
11. Huang LZ, Wang J, Lu FT, Yang FC, Chen X, Hong X. et al. Mechanism study on anti-proliferative effects of curcumol in human hepatocarcinoma HepG2 cells. Zhongguo Zhong Yao Za Zhi. 2013; 38: 1812-1815.
12. Zang S, Tang Q, Dong F, Liu H, Li L, Guo F. et al. Curcumol inhibits the proliferation of gastric adenocarcinoma MGC-803 cells via downregulation of IDH1. Oncol Rep. 2017; 38: 3583-3591.
13. Lee TK, Lee D, Lee SR, Ko YJ, Sung KK, Chung SJ. et al. Sesquiterpenes from Curcuma zedoaria rhizomes and their cytotoxicity against human gastric cancer AGS cells. Bioorg Chem. 2019, 87: 117-122.
14. Cai F, Chen M, Zha D, Zhang P, Zhang X, Gao N. et al. Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer. Oncotarget. 2017; 8: 115526-115545.
15. Zhang W, Wang Z, Chen T. Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lungadenocarcinoma ASTC-a-1 cells. Med Oncol. 2011; 28: 307-314.
16. Tang QL, Guo QJ, Wang QY, Lin HS, Yang ZP, Peng T. et al. Curcumol induces apoptosis in SPC-A-1 human lung adenocarcinoma cells and displays anti-neoplastic effects in tumor bearing mice. Asian Pac J Cancer Prev. 2015; 16: 2307-2312.
17. Walter B A, Valera V A, Pinto PA, Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. J Cancer. 2013; 4: 350-357.
18. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19: 92-105.
19. Chen Y, Song YX, Wang ZN. The microRNA-148-152 family: Multi-faceted players. Molecular Cancer. 2013; 12: 43.
20. Ghazanchaei A, Mansoori B, Mohammadi A, Biglari A, Baradaran B. 2015. Structure of curcumenol. Chem Pharm Bull. 1968; 16: 39-42.
21. Trotter SC, Seo N, Winkelmann RR, Olencki T, Bechtle M. A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol. 2013; 6: 18-26.
22. Lines E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009; 129: 1666-1674.
23. Membership of the 5th Pharmacopoeia Commission, Pharmacopoeia Commission of PRC,Pharmacopoeia of the People’s Republic of China (English edition). Chemical Industry Press: Beijing. 2000.
24. Hikino H, Sakurai Y, Numabe S, Takeomo T. Structure of curcumol. Chem Pharm Bull. 1968; 16: 39-42.
25. Gao P, Wang YW, Weng BX, Li XK, Yang SL, Ye FQ. Synthesis, anti-tumor activity, and structure-activity relationships of curcumol derivatives. J Asian Nat Prod Res. 2014; 16: 53-58.
26. Jiang Y, Li ZS, Jiang FS, Deng X, Yao CS, Nie G. Effects of different ingredients of zedoary on gene expression of HSC-T6 cells. World Journal of Gastroenterology. 2005; 11: 6789-6796.
27. Chen G, Wang Y, Li M, Xu T, Wang X, Hong B. et al. Curcumol induces HSC-T6 cell death through suppression of Bcl-2 involvement of PI3K and NF-κB pathways. Eur J Pharm Sci. 2014; 65: 21-28.
28. Huang LZ, Wang J, Lu FT, Yang FC, Chen X, Hong X. et al. Mechanism study on anti-proliferative effects of curcumol in human hepatocarcinoma HepG2 cells. Zhongguo Zhong Yao Za Zhi. 2013; 38: 1812-1815.
29. Zang S, Tang Q, Dong F, Liu H, Li L, Guo F. et al. Curcumol inhibits the proliferation of gastric adenocarcinoma MGC-803 cells via downregulation of IDH1. Oncol Rep. 2017; 38: 3583-3591.
30. Lee TK, Lee D, Lee SR, Ko YJ, Sung KK, Chung SJ. et al. Sesquiterpenes from Curcuma zedoaria rhizomes and their cytotoxicity against human gastric cancer AGS cells. Bioorg Chem. 2019, 87: 117-122.
31. Cai F, Chen M, Zha D, Zhang P, Zhang X, Gao N. et al. Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer. Oncotarget. 2017; 8: 115526-115545.
32. Zhang W, Wang Z, Chen T. Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lungadenocarcinoma ASTC-a-1 cells. Med Oncol. 2011; 28: 307-314.
33. Tang QL, Guo QJ, Wang QY, Lin HS, Yang ZP, Peng T. et al. Curcumol induces apoptosis in SPC-A-1 human lung adenocarcinoma cells and displays anti-neoplastic effects in tumor bearing mice. Asian Pac J Cancer Prev. 2015; 16: 2307-2312.
24. Luan WK, Li R, Liu L, Ni X, Shi Y, Xia Y. et al. Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p. Oncotarget. 2017; 8: 85401-85414.

25. McIvor L, J.L. Matrisian L.M. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000; 6: 149-156.

26. Abitha J, Ryts P. The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol. 2015; 3: 1-9.

27. uiber MA, Kaznut N, Brug, H. Molecular requirements for epithelial mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17: 548-558.

28. Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016; 43: 7-13.

29. Yan DZ, Deng S, Gan W, Li S, Li Y. Curcumin attenuates epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via TGF-β1. Mol Med Rep. 2018; 17: 7513-7520.

30. Gardner FP, Serie DJ, Salomao DR, Wu KJ, Markovic SN, Pulido JS. et al. TGF-β1 reduces migration and invasion of murine metastatic melanoma cells by suppressing MMP2/9 expression and PTEN. Mol Carcinog. 2017; 56: 886-894.

31. Mao XH, Chen M, Wang Y, Cui PG, Liu SB, Xu ZY. MicroRNA-21 regulates apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and the ERK/NF-κB pathway. Acta Biochim Biophys Sin. 2015; 47: 292-298.

32. Li M, Wang X, Wang Y, Zhao C, Wang L. Function of miR-152 as tumor suppressor in oral squamous cell carcinoma cells by targeting c-MET. Oncol Rep. 2018; 39: 1173-1180.

33. Tracey E.H, Vij A. Updates in melanoma. Dermatol Clin. 2019; 37: 73-82.

34. Li M, Wang X, Tao Y, Li X, Qin J, Bai Z. et al. Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN/PI3K/Akt pathway. Life Sci. 2019; 221: 354-361.

35. Li M, Wang X, Tao Y, Li X, Qin J, Bai Z. et al. Curcumol induces cell cycle arrest and apoptosis by inhibiting IGF-IR/PI3K/Akt signaling pathway in human nasopharyngeal carcinoma CNE-2 cells. Phytother Res. 2018; 32: 2214-2225.

36. Zhao G, Han X, Zheng S, Li Z, Sha Y, Ni J. et al. Curcumin induces autophagy, inhibits proliferation and invasion by downregulating Akt/mTOR signaling pathway in human melanoma cells. Oncol Rep. 2016; 35: 1065-1074.

37. Al-Ud'dat DGF, Al-Husein BAA, Qasameh GRA. mini-review of c-Met as a potential therapeutic target in melanoma. Biomed Pharmacother. 2017; 88: 194-202.

38. Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munihi R. et al. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 2015; 135: 2283-2291.

39. Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology. 2003; 65: 72-82.

40. Czyz M. HGF/c-MET Signaling in Melanocytes and Melanoma. Int J Mol Sci. 2018; 19. E13844.

41. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF. et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA. 2001; 98: 247-252.

42. Chatteraj D, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS ONE. 2014; 9: e83957.

43. Tang Q, Wang L, Tu Y, Zhu W, Luo R, Tu Q. et al. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing L,3-triazole moiety as c-Met kinase inhibitors. Bioorg Med Chem Lett. 2016; 26: 1680-1684.

44. Brenceneck J, Hiepner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the prosurvival gene hid in Drosophila. Cell. 2003; 113: 25-36.

45. Wang XY, Wu MF, Liu F, Li Y, Li N, Li GY. et al. Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol Cell Biochem. 2010; 345: 283-290.

46. Zhao W, Zhao SP, Zhao HY. MicroRNA-143/-145 in cardiovascular diseases. Biomed Res Int. 2015; 2015: 531740.

47. Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y. et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 2013; 5: 3-13.